PP2A Cancerous-IN-1 是一种强效的CIP2A(Cancerous inhibitor of PP2A)和p-Akt抑制剂。PP2A Cancerous-IN-1显示出很强的抗增殖活性。

PP2A Cancerous-IN-1 is a strong and potent CIP2A (Cancerous inhibitor of PP2A) and p-Akt inhibitor. PP2A Cancerous-IN-1 shows the most potent antiproliferative activities [1].

PP2A Cancerous-IN-1 (2.5 and 5 μM; 24 hours; SK-Hep-1 cells) reduces CIP2A expression and cell viability with a dose dependent manner and is more potent in its action than erlotinib [1]. PP2A Cancerous-IN-1 (5 μM; 24 hours; SK-Hep-1 cells) induces cell apoptosis [1]. PP2A Cancerous-IN-1 shows CIP2A inhibitory activity, reduces p-Akt level, induces PARP cleavage. PP2A Cancerous-IN-1 exhibits high potency with low IC50 values of 2.8 μM against HCC cells [1]. Cell Viability Assay [1] Cell Line: SK-Hep-1 cells Concentration: 2.5 and 5 μM Incubation Time: 24 hours Result: Reduced cell viability with a dose dependent manner. Western Blot Analysis [1] Cell Line: SK-Hep-1 cells Concentration: 2.5 and 5 μM Incubation Time: 24 hours Result: Reduced CIP2A expression. Apoptosis Analysis [1] Cell Line: SK-Hep-1 cells Concentration: 2.5 and 5 μM Incubation Time: 24 hours Result: Induced cell apoptosis.

1403933-79-8

C30H24N4O3

488.54

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years